BioDelivery Sciences International, Inc. (BDSI) - Financial and Strategic Analysis Review by GlobalData

VIEWS: 12 PAGES: 32

More Info
									        BioDelivery Sciences International, Inc. (BDSI) - Financial and Strategic
                                   Analysis Review

       Reference Code: GDPH4235FSA                                                                                        Publication Date: SEP 2010

       801 Corporate Center Drive,           Phone                                                 Revenue
                                                               +1 919 5829050                                        62.8 (million USD)
       Suite 205
       Raleigh, NC                           Fax               +1 919 5829051                      Net Profit        33.05 (million USD)
       27607                                 Website           www.bdsi.com                        Employees         16
       United States                         Exchange          BDSI [NASDAQ]                       Industry          Pharmaceuticals & Healthcare

       Company Overview
       BioDelivery Sciences International, Inc. (BDSI) is a publicly held specialty pharmaceutical company. The company is engaged on
       the development and commercialization of new formulations of proven therapeutics by utilizing its proprietary drug delivery
       technologies. BDSI's patented drug delivery technologies include: BEMA (BioErodibleMucoAdhesive), which consists of a small
       dissolvable polymer film for application to mucosal membranes for transmucosal delivery of drugs for time critical conditions and
       Bioral, which is based upon a novel process of encapsulating or protecting a drug to facilitate oral dosing of drugs otherwise
       given by intravenous administration.

      Key Executives                                                                 SWOT Analysis
                     Name                                   Title                    BioDelivery Sciences International, Inc., SWOT Analysis
       Frank E. O'Donnell, Jr., M.D.        Chairman                                 Strengths                    Weaknesses

       Mark A. Sirgo                        Chief Executive Officer
                                                                                     Approval of Onsolis                  Litigations
       William B. Stone                     Director
       John J. Shea                         Director                                 Intellectual Property                Limited Liquidity Position
       William S. Poole                     Director
       Source: Annual Report, Company Website, Primary and Secondary Research
       GlobalData
                                                                                     Opportunities                        Threats
      Share Data
                                                                                     Licensing and Development            Intense Competition
       BioDelivery Sciences International, Inc.                                      Agreement with Meda
       Share Price (USD) as on 08-Sep-2010                                 2.60                                           Pricing Pressures
                                                                           1.54      Changing Demographics
       EPS (USD)
       Market Cap (million USD)                                                 61

       Enterprise Value (million USD)                                           36
                                                                                     Source: Annual Report, Company Website, Primary and Secondary Research
       Shares Outstanding (million)                                             24   GlobalData
       Source: Annual Report, Company Website, Primary and Secondary Research
       GlobalData

       Financial Performance                                                         Recent Developments
                                                                                     Sep 07,
								
To top